An intriguing observation was that AML patients with IDH mutations (either IDH1 or IDH2) showed high remission rates with an OS of 24.5 months and a composite complete remission CRc (CR + CRi) rate of 79% when treated with VEN-AZA (17). Here, IDH2 is linked to acute myeloid leukemia.